Related Experiment Video
Updated: Mar 16, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Chronic Treatment with Ivabradine Does Not Affect Cardiovascular Autonomic Control in Rats
Fernanda C Silva1, Franciny A Paiva1, Flávia C Müller-Ribeiro2
1Laboratory of Cardiovascular Physiology, Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro PretoOuro Preto, Brazil; Graduate Program in Biological Sciences - CBIOL/NUPEB, Federal University of Ouro PretoOuro Preto, Brazil.
Insights
Ivabradine effectively lowers heart rate (HR) in rats by acting on hyperpolarization-activated cyclic nucleotide gated (HCN) channels. This study found that chronic ivabradine treatment reduces resting HR without altering autonomic control or renal sympathetic nerve activity (RSNA).
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Autonomic Nervous System Research
Background:
- A low resting heart rate (HR) is beneficial for cardiovascular diseases.
- Ivabradine, a selective hyperpolarization-activated cyclic nucleotide gated (HCN) channel inhibitor, is a promising HR-lowering drug.
- The effects of ivabradine on autonomic HR control are not well understood.
Purpose of the Study:
- To assess the impact of chronic ivabradine treatment on cardiovascular autonomic control.
- To investigate the effects of ivabradine on reflex and tonic autonomic control of HR.
- To evaluate the influence of ivabradine on renal sympathetic nerve activity (RSNA).
Main Methods:
- Male Wistar rats received daily intraperitoneal injections of vehicle (VEH) or ivabradine (IVA) for 7-8 days.
- Arterial blood pressure (AP) and HR were recorded in freely moving rats, with cardiovascular variability parameters analyzed.
- Baroreflex, chemoreflex, Bezold-Jarish reflex sensitivities, and autonomic blockade were assessed; AP, HR, and RSNA were recorded in anesthetized rats.
Main Results:
- Ivabradine-treated rats exhibited significantly lower resting and intrinsic HR compared to controls.
- Chronic ivabradine treatment did not alter normalized HR spectral parameters (LF (nu), HF (nu)).
- No significant changes were observed in cardiovascular reflex sensitivities, tonic autonomic control of HR, RSNA, or mean arterial pressure.
Conclusions:
- In healthy rats, long-term ivabradine treatment directly reduces HR.
- Ivabradine does not affect RSNA modulation or the reflex and tonic autonomic control of the heart.
- Ivabradine demonstrates potential as an HR-lowering agent with specific effects on HCN channels, independent of broad autonomic modulation.
Abstract:
A low resting heart rate (HR) would be of great benefit in cardiovascular diseases. Ivabradine-a novel selective inhibitor of hyperpolarization-activated cyclic nucleotide gated (HCN) channels- has emerged as a promising HR lowering drug. Its effects on the autonomic HR control are little known. This study assessed the effects of chronic treatment with ivabradine on the modulatory, reflex and tonic cardiovascular autonomic control and on the renal sympathetic nerve activity (RSNA). Male Wistar rats were divided in 2 groups, receiving intraperitoneal injections of vehicle (VEH) or ivabradine (IVA) during 7 or 8 consecutive days. Rats were submitted to vessels cannulation to perform arterial blood pressure (AP) and HR recordings in freely moving rats. Time series of resting pulse interval and systolic AP were used to measure cardiovascular variability parameters. We also assessed the baroreflex, chemoreflex and the Bezold-Jarish reflex sensitivities. To better evaluate the effects of ivabradine on the autonomic control of the heart, we performed sympathetic and vagal autonomic blockade. As expected, ivabradine-treated rats showed a lower resting (VEH: 362 ± 16 bpm vs. IVA: 260 ± 14 bpm, p = 0.0005) and intrinsic HR (VEH: 369 ± 9 bpm vs. IVA: 326 ± 11 bpm, p = 0.0146). However, the chronic treatment with ivabradine did not change normalized HR spectral parameters LF (nu) (VEH: 24.2 ± 4.6 vs. IVA: 29.8 ± 6.4; p > 0.05); HF (nu) (VEH: 75.1 ± 3.7 vs. IVA: 69.2 ± 5.8; p > 0.05), any cardiovascular reflexes, neither the tonic autonomic control of the HR (tonic sympathovagal index; VEH: 0.91± 0.02 vs. IVA: 0.88 ± 0.03, p = 0.3494). We performed the AP, HR and RSNA recordings in urethane-anesthetized rats. The chronic treatment with ivabradine reduced the resting HR (VEH: 364 ± 12 bpm vs. IVA: 207 ± 11 bpm, p < 0.0001), without affecting RSNA (VEH: 117 ± 16 vs. IVA: 120 ± 9 spikes/s, p = 0.9100) and mean arterial pressure (VEH: 70 ± 4 vs. IVA: 77 ± 6 mmHg, p = 0.3293). Our results suggest that, in health rats, the long-term treatment with ivabradine directly reduces the HR without changing the RSNA modulation and the reflex and tonic autonomic control of the heart.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System